OPENING of Abstract Submissions: October 31, 2020
CLOSING of Abstract Submissions: January 11, 2021
CUA 2021 ABSTRACT
CHANGES TO THE SUBMISSION TERMS FOR 2021
- Abstracts that have been accepted for presentation at another major urological meeting before June 28, 2021 must be disclosed in the ”acknowledgments” step of abstract submission. Please also inform the Abstract Manager (firstname.lastname@example.org) if your abstract was/ will be published before June 28, 2021.
- Case Studies are NOT accepted as abstracts.
October 31, 2020
January 11, 2021
Notification email will be sent
March 2, 2021
Deadline for presenters to accept invitation
March 16, 2021
Deadline for presenter to register
April 1, 2021
A. SUBMISSION TERMS
- Rule of two: Each presenter can present a total of two oral presentations (podium or moderated poster) during CUA 2021. This restriction does not apply to “unmoderated posters”.
- Abstracts must be written and presented in English.
- Submitted abstracts undergo a blind review by peer-reviewers. Acceptance is based on scientific merit and originality. Please note that case studies are not permitted.
- While abstracts may be submitted as podium, moderated poster, or unmoderated poster presentation types, the Scientific Committee reserves the right to assign final presentation type in the best interest of the program.
- Multiple abstracts by the same authors based on the same study population or data may be disqualified without further consideration.
- The work covered by the abstract should not have been published as a manuscript before June 28, 2021. Abstracts that have been accepted for presentation at another major urological meeting must be disclosed in the ”acknowledgments” step of abstract submission. Please also inform the Abstract Manager (email@example.com).
- Trials in progress can be submitted, but please note the committee will review and take into account whether or not the information is presentable or not with the data accumulated.
- Cast Studies are not accepted as abstracts.
- In regards to production deadlines, as of April 1, 2021, all presenting authors must be registered and must have paid their registration fees to keep their abstract in the program. Any changes to the presenting author will not be reflected in the CUAJ after this date.
- Authors are responsible for proofreading their abstract before submitting, particularly with regard to general orthography, as well as author names/order and affiliations. CUAJ will edit all submissions for consistency and formatting.
B. ABSTRACT FORMAT
- The title should clearly define the topic and contain no abbreviations.
- There is a character limit of 200 characters including spaces.
- Enter the title as you were writing a sentence, Only CAPITALIZE the first letter of the sentence and proper nouns, nothing else.
- Do not use punctuation at the end of the sentence UNLESS it is a question mark (?) or exclamation point (!)
- No symbols are permitted; write out the name of the symbol (i.e. save beta, alpha, etc.). You will be allowed to use symbols for the abstract body.
- The size of the abstract is limited to 2000 characters including spaces (or approx. 400 words). This includes body of abstract only.
- The body must contain four separate paragraphs: a) Introduction; b) Methods; c) Results; and d) Conclusions. The abstract should be informative and detailed.
- Standard abbreviations may be used as follows: on first use, spell out the full term and follow with abbreviation in parentheses. Abbreviations can be used subsequently.
- Use generic names of drugs.
- It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is necessary for reviewers.
- Indicate the major new findings of the study.
- References are not required.
- Study Groups/Acknowledgements: These will be noted above your abstract in the CUAJ.
- To insert a figure (image, table or graph) please upload the files as a JPG in the “Figures” step
- All tables/graphs must be titled and all images/figures must have a caption.
- All figures (image, table, or graph) will only be published in the Annual Meeting web app. They will not be published in the printed journal.
- Reference to accompanying figures must be made within the body of the abstract (i.e., Patient demographics are listed in Table 1). For the printed journal, readers will be directed to view figures on the web app.
- Take care to list ALL authors in the relevant section of the submission site. Spell out completely the names of all authors using full first and last names.
- Middle name initials are to be placed in the special field for this. It should be a capital letter with a period at the end. (i.e. Stephanie M. Smith)
- Maintain consistency in author names on multiple abstracts to avoid duplication in the Author Index.
- Affiliations (department, institution) should be spelled out in full.
- Presenting Author: If the author(s) of the abstract is an employee(s) of, or has a financial relationship with, the commercial interest, which controls the content of the presentation, he/she cannot be the presenting author. However, investigators responsible for research and development are permitted to present as long as they resolve their Conflict of Interest (COI) and as long as they are not employees of the commercial interest. In all printed publications the presenting author will be underlined.
- Conflict of Interest and Disclosure Statement: This is required for the submitting author and the presenting author. It is the responsibility of the submitting author to collect this information.
- Topic List: Authors must select an abstract topic (only one) from the provided list:
Endourology - Nephrolithiasis
Endourology – Laparoscopy/ Robotics
Improving Patient Relations/ Practice Management/ Communications
Technical Advances in Urology
Lower Urinary Tract Reconstruction and Genitourinary Trauma
Training and Evaluation
Male/Female Pelvic Pain
Oncology - Bladder
Oncology - General Oncology
Oncology - Kidney & Ureter
Oncology - Penis/Testis/Urethra
Oncology - Prostate
Sexual Dysfunction and Infertility
Urinary Incontinence and Voiding Dysfunction
Urological Infections (Includes STDs)